The vaccine, called mRNA-1273, was developed by scientists and researchers in the laboratories of the US National Institute of Public Health at the laboratory of the biotechnology Moderna, located in Cambridge. Massachusetts.

The research was sponsored by the Coalition for Epidemic Preparedness Innovations in Oslo, Norway.

The first test subjects were vaccinated on March 16. This trial must ensure that it is effective and safe for people. The first phase of the trial was conducted with a total of 45 patients both male and female, between the ages of 18-55 and not pregnant.

This move of the US government occurred after German media reported sources as saying that the US government had offered a large sum of money to a German medical company requesting exclusive access to the Covid-19 vaccine.

Trump reportedly offered a huge amount of money to Tübingen-based biopharmaceutical company CureVac to secure the vaccine “only for the United States”.